Purpose of icariin in preparation of medicines used for treating bronchial asthma
A technique for bronchial asthma and icariin, applied in the field of biomedicine
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2012-02-01
- Estimated Expiration
- Not applicable · inactive patent
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of biomedicine and relates to a new medicinal application of icariin, an active ingredient of traditional Chinese medicine, in particular to the application of icariin in the preparation of medicines for preventing and treating bronchial asthma. Background technique
[0002] Asthma is a chronic airway inflammatory disease. According to reports, its morbidity and mortality are increasing year by year, seriously threatening people's physical and mental health. Pathological studies on bronchial asthma have shown that a variety of inflammatory cells, cytokines and inflammatory mediators constitute a complex inflammatory network and participate in the occurrence and development of asthma. Previous studies have shown that the water decoction of Chinese herbal medicine Epimedium has a certain intervention effect on asthma, but the preventive and therapeutic effects have not yet appeared.
[0003] Icariin is the main effect...
Examples
Embodiment 1
[0019] (1) Experimental animals and grouping: Healthy and clean male SD rats, weighing 350±10 g, were purchased from Sichuan Bill Experimental Animal Company. The animals were kept in the Experimental Animal Center of Fudan University, and the feeding conditions were clean, with fixed light time and free intake of water and food. Animals were divided into 6 groups, including blank control group, model group, and icariin (low, medium, high dose) intervention group. The low dose is 5mg / kg, the medium dose is 10mg / kg, and the high dose is 20mg / kg. The administration method is intraperitoneal injection, once a day, for a total of 28 days.
[0020] (2) Main reagents and instruments: ovalbumin (Shanghai Livzon Dongfeng Biotechnology Co., Ltd.); aluminum hydroxide gel (Sigma.Co.); sodium pentobarbital (Shanghai Chemical Reagent Company, imported repackaging); IL -4, 13 kits (Biosource imported packaging); corticosterone kit (R & D company); ACTH radioimmunoassay kit (Institute of N...